Retatrutide is an engineered peptide that activates the receptors for GIP, GLP-1 and glucagon. Its development combines appetite and glucose regulation with glucagon-related metabolic effects in one molecule. Published phase 3 trials now show substantial weight reduction in adults both with and without type 2 diabetes, and a separate diabetes programme has demonstrated improved glucose control. The differences between those populations, their endpoints and the way investigators handled treatment discontinuation explain much of the variation in the reported results. Retatrutide remains investigational as of October 13, 2026. Jastreboff et al. (2026), Bellido et al. (2026), Lilly (2026).
Overview
Molecular profile
The development name LY3437943 and the name retatrutide refer to the same triple receptor agonist. Coskun and colleagues characterised its activity at human GIP, GLP-1 and glucagon receptors and its albumin-binding modification. Albumin is an abundant blood protein; reversible association with it helps extend the time an engineered peptide remains in circulation. This chemical design makes prolonged receptor exposure possible, while the clinical trials determine the resulting benefits and adverse effects. Coskun et al. (2022).
Uses and research areas
The principal research areas are obesity and type 2 diabetes. Trials also examine obesity-related complications, including knee osteoarthritis and obstructive sleep apnea. These conditions provide clinically relevant outcomes beyond the number on a scale: pain affects mobility, and disrupted breathing affects sleep and cardiometabolic health. In TRIUMPH-1, the investigators assessed those complications in defined subsets of the obesity trial rather than in every participant. Jastreboff et al. (2026).
The diabetes studies address a separate physiological question. A peptide with glucagon receptor activity must achieve a favourable overall effect on glucose despite glucagon's capacity to stimulate hepatic glucose production. Measurements of HbA1c, which reflects average glycaemia over preceding months, therefore matter directly to this programme. Rosenstock et al. (2023).
Mechanism of action
GIP and GLP-1 are nutrient-related hormones that enhance insulin secretion in a glucose-dependent manner. GLP-1 receptor activation also engages appetite regulation and can slow gastric emptying. Glucagon acts prominently in the liver, where it changes the handling of glucose, amino acids and fat. Retatrutide brings these receptor activities together, so its clinical effect reflects their interaction over sustained exposure.
The discovery experiments linked retatrutide's weight effect in obese mice to reduced food intake and increased energy expenditure. The latter provides a biological reason to study glucagon-containing agonists. Human weight trials measure the combined intervention: they do not assign a percentage of weight loss to each receptor. Receptor activity in a laboratory assay establishes which targets the molecule can engage; energy balance and clinical outcomes require their own measurements. Coskun et al. (2022).
Pharmacokinetics
Urva and colleagues studied LY3437943 in a phase 1b trial in people with type 2 diabetes. Blood exposure rose approximately in proportion to the amount studied, and the reported elimination half-life was about six days after subcutaneous administration. That half-life describes the time for the concentration to fall by half during elimination. It does not specify when every clinical effect disappears. During repeated treatment, absorption and accumulation also affect the concentration. Urva et al. (2022).
Population: Adults with type 2 diabetes in the phase 1b LY3437943 trial. Administration: Subcutaneous study administration; model begins after absorption. Analyte: Plasma LY3437943 (retatrutide).
Urva and colleagues (2022) reported an approximate six-day half-life after subcutaneous LY3437943 in adults with type 2 diabetes. The calculated curve starts at 100% in the elimination phase and follows C/C0 = 2^(-t/6), with time in days. The accessed abstract supplies no numerical uncertainty for this estimate. Absorption and accumulation during repeated treatment have their own time courses and require further measurements.
Urva S, Coskun T, Loh MT, et al. (2022). LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet 400(10366):1869–1881. DOI: 10.1016/S0140-6736(22)02033-5. Urva et al. (2022), Abstract Findings: approximately six-day half-life.
Research findings
From the phase 2 obesity trial to TRIUMPH-1
The 338-participant phase 2 obesity trial excluded diabetes. At its primary 24-week endpoint, the largest reported group-average reduction was 17.5%, compared with 1.6% with placebo. At the secondary 48-week endpoint, the corresponding reductions were 24.2% and 2.1%. These were estimates under an efficacy estimand, a defined analysis intended to describe the effect if treatment was administered as planned. The 24.2% result became widely quoted, although the trial's primary outcome occurred earlier. Jastreboff et al. (2023).
TRIUMPH-1 extended observation to 80 weeks in 2,339 adults with obesity without diabetes. Mean weight changes were −17.6%, −23.7% and −25.0% in the assigned 4-, 9- and 12-mg groups, versus −3.9% with placebo. The weight analysis used a treatment-regimen estimand consistent with intention to treat, incorporating outcomes associated with treatment interruption or discontinuation. The trial also reported improved osteoarthritis pain in its 574-participant knee subgroup. Those complication endpoints used a hybrid estimand, with intention-to-treat results reported separately, so their analyses should remain distinct from the weight analysis. Jastreboff et al. (2026).
Glucose control and weight in diabetes populations
The earlier phase 2 diabetes trial randomised 281 participants, with 275 included in efficacy analyses after six inadvertent enrolments were excluded. Investigators compared six retatrutide groups with placebo and with dulaglutide, an active diabetes medicine. At 24 weeks, HbA1c fell by 0.43 to 2.02 percentage points across the retatrutide groups, compared with 0.01 with placebo and 1.41 with dulaglutide. All except the smallest retatrutide assignment lowered HbA1c significantly more than placebo; two lowered it significantly more than dulaglutide in the specified comparisons. Weight at 36 weeks was a separate secondary outcome. Rosenstock et al. (2023).
TRANSCEND-T2D-1 studied retatrutide monotherapy in 537 adults whose diabetes was inadequately controlled with diet and exercise alone. At 40 weeks, treatment-regimen HbA1c changes were −1.69, −1.86 and −1.94 percentage points in the three active groups, versus −0.81 with placebo. Weight reductions ranged from 11.5% to 15.3%, versus 2.6%. This population had relatively early diabetes, with a mean disease duration of 2.5 years. Bajaj et al. (2026).
TRIUMPH-2 studied 1,152 adults with obesity and type 2 diabetes over 80 weeks; 92% were already taking an oral glucose-lowering medicine at baseline. Treatment-regimen mean weight changes were −11.9%, −16.8% and −18.8% across the three active groups, versus −5.1% with placebo. The diabetes populations and background treatments make these results useful complements to TRIUMPH-1 rather than interchangeable estimates of an individual's response. Bellido et al. (2026).
Safety and tolerability
Gastrointestinal events recur across the retatrutide trials. In the phase 2 obesity study, heart-rate increases peaked at 24 weeks and subsequently declined. TRIUMPH-2 also found more hypotension and dysesthesia, an altered or unpleasant skin sensation, with retatrutide. Dysesthesia occurred in 4%–7% of active-group participants versus 1% with placebo. Permanent discontinuation because of adverse events or death occurred in 12% and 8% of the two higher-assignment groups, compared with 4% in the lowest group and 5% with placebo. Investigators considered the reported deaths unrelated to the intervention. These observations make tolerability and treatment continuation integral to interpretation of the weight results. Jastreboff et al. (2023), Bellido et al. (2026).
Lilly's September 2026 status information states that retatrutide has not been approved by a regulatory agency. The clinical findings concern the trial formulation and supervised study populations; long-term cardiovascular and renal outcomes remain part of its development programme. Lilly (2026).
What the research means
Retatrutide's evidence now reaches beyond the early phase 2 weight result. Larger trials demonstrate weight reduction across different metabolic populations, and direct diabetes trials establish glucose lowering alongside the glucagon-containing mechanism. The treatment-regimen analyses also account for more of the experience of being assigned the treatment than an idealised adherence analysis does.
The next comparative questions require trials in which participants share the same eligibility criteria, follow-up and analysis. A larger percentage from one placebo-controlled trial cannot establish superiority over a medicine studied elsewhere. Likewise, improvements in weight, HbA1c or an obesity-related symptom do not establish fewer cardiovascular events; those outcomes need the dedicated studies now under way.
FAQs
Why do weight percentages differ between trials?
Trials differ in whether participants have diabetes, which other medicines they take and how long they are followed. They also handle stopping or changing treatment differently. An efficacy analysis estimates the result if treatment is taken as planned; a treatment-regimen analysis includes the experience of participants who stop treatment. A weight-loss percentage is therefore most useful alongside its population, follow-up and analysis method.
Does triple agonism establish superiority over tirzepatide?
It establishes a receptor profile. Comparative superiority requires a direct trial with shared eligibility, follow-up and outcome analysis.
What does the six-day half-life describe?
The early diabetes trial reported an approximately six-day elimination estimate. Clinical effects also depend on absorption, repeated exposure and biological response.
Comparisons and related reading
Retatrutide combines three receptor activities in one molecule. Tirzepatide provides the closest GIP/GLP-1 comparison, while survodutide and mazdutide help explain why developers include glucagon receptor activity. CagriSema uses two separately identified peptide components to combine GLP-1 and amylin-family signalling.
References
The phase 2 obesity trial separates the primary 24-week result from the widely cited secondary 48-week weight outcome.
TRIUMPH-1 reports phase 3 weight outcomes and separate complication-subgroup analyses.
TRIUMPH-2 examines weight and tolerability in adults with obesity and type 2 diabetes.
The discovery report establishes triple receptor activity and links weight effects in mice to intake and energy-expenditure measurements.
The phase 2 diabetes trial measures HbA1c and distinguishes efficacy and safety populations.
The phase 1b trial supplies the approximately six-day human elimination estimate.
TRANSCEND-T2D-1 establishes phase 3 monotherapy glucose and weight effects in early diabetes.
The manufacturer identifies retatrutide as investigational and describes ongoing programmes.
Glossary
- GIP
- Glucose-dependent insulinotropic polypeptide, a nutrient-related hormone involved in insulin secretion.
- GLP-1
- Glucagon-like peptide-1, a gut hormone involved in glucose regulation and appetite.
- Glucagon
- A pancreatic hormone that affects hepatic glucose production and other metabolic processes.
- Estimand
- The precisely defined treatment effect a trial analysis estimates, including how treatment changes are handled.
- HbA1c
- Glycated haemoglobin, reflecting average blood glucose over preceding months.
- Dysesthesia
- An altered or unpleasant sensation, often affecting the skin.
- Albumin
- An abundant blood protein whose binding can prolong engineered peptide exposure.